Page last updated: 2024-11-11

benazepril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benazepril: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5362124
CHEMBL ID838
CHEBI ID3011
SCHEMBL ID16396
MeSH IDM0130973

Synonyms (88)

Synonym
BIDD:GT0800
AKOS005560204
BRD-K49807096-003-02-3
benazeprilum
CHEBI:3011 ,
1h-1-benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (s-(r*,r*))-
cgs-14824a
[(3s)-3-{[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}-2-oxo-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl]acetic acid
[(3s)-3-({(1s)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl]acetic acid
SPECTRUM_001922
hsdb 7081
lotrel
benazepril [inn:ban]
benzazepril
benazeprilum [latin]
benazapril
cgs-14824-a
forteekor [veterinary] (tn)
benazepril (inn)
benazepril sandoz (tn)
D07499
BSPBIO_003487
SPECTRUM5_001546
C06843
86541-75-5
benazepril
DB00542
NCGC00165740-01
KBIO3_002707
KBIO2_002457
KBIOSS_002464
KBIO2_005025
KBIOGR_000812
KBIO2_007593
SPECTRUM2_000482
SPECTRUM4_000286
SPECTRUM3_001674
SPBIO_000343
NCGC00165740-02
c09aa07
cibacen ws
forteekor
benazepril sandoz
CHEMBL838 ,
2-[(3s)-3-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid
STK627447
[(3s)-3-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl]acetic acid
bdbm50021153
A841713
2-[(3s)-3-[[(1s)-1-ethoxycarbonyl-3-phenyl-propyl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid;benazepril
NCGC00165740-03
udm7q7qwp8 ,
unii-udm7q7qwp8
NCGC00165740-04
S5938
gtpl6374
benazepril [who-dd]
((3s)-3-(((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2-oxo-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl)acetic acid
benazepril [vandf]
benazepril [inn]
benazepril [mi]
1h-1-benzazepine-1-acetic acid, 3-(((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (3s)-
benazepril [ema epar veterinary]
BBL034011
HY-B0093
CS-1795
SCHEMBL16396
AB00698518-07
smr000857173
MLS006011854
1h-1-benzazepine-1-acetic acid, 3-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3s)-
AB00698518_09
AB00698518_08
DTXSID5022645 ,
2-[(3s)-3-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl]acetic acid
mfcd00864466
SBI-0206744.P001
109010-10-8
2-((s)-3-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)-2-oxo-2,3,4,5-tetrahydro-1h-benzo[b]azepin-1-yl)acetic acid
Q592802
BCP12672
benazepril impurity a
tert butyl-3-(3s)amino-2,3,4,5-tetrahydro-1h(1)benzazepin-2-one-1-acetate
forteekor (veterinary)
benazepril (ema epar veterinary)
dtxcid602645
benazeprilum (latin)
EN300-6481298

Research Excerpts

Overview

Benazepril hydrochloride is a non-sulfhydryl-containing, angiotensin-converting enzyme (ACE) inhibitor. It can be safely used in renal and liver disease. Benzepril is a prodrug that, following rapid conversion to benazeprillat, is a pot.

ExcerptReferenceRelevance
"Benazepril is a commonly employed anti-hypertensive medication, and we report an unusual condition associated with this medication in order to increase vigilance among caregivers. "( Benazepril-Induced Agranulocytosis: A Case Report and Review of the Literature.
Hashmi, HR; Jabbour, R; Khaja, M; Schreiber, Z, 2016
)
3.32
"Benazepril is a nonsulfhydryl ACE inhibitor with favorable pharmacodynamic and pharmacokinetic properties, well-established antihypertensive effects and a good tolerability profile. "( Antihypertensive and organ-protective effects of benazepril.
Barrios, V; Escobar, C, 2010
)
2.06
"Benazepril hydrochloride is a non-sulfhydryl-containing, angiotensin-converting enzyme (ACE) inhibitor. "( Short-term and long-term effects of benazepril in mild to moderate hypertensives.
Chang, MS; Chen, CH; Chou, P; Hsu, TL; Lin, SJ; Ting, CT; Wang, SP; Yin, FC, 1995
)
2.01
"Benazepril (Lotensin) is an ACE inhibitor that can be safely used in renal and liver disease. "( Benazepril: a new ACE inhibitor.
Bell, J, 1993
)
3.17
"Benazepril is a well-tolerated angiotensin-converting enzyme inhibitor that provides clinically important improvement in exercise tolerance and in signs and symptoms when given once daily to patients with CHF receiving background therapy with digoxin and a diuretic."( Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The Benazepril Heart Failure Study Group.
Colfer, HT; Gradman, A; Hughes, CV; Kapoor, A; Laidlaw, JC; Ribner, HS, 1992
)
1.32
"Benazepril is a nonsulfhydryl ACE inhibitor prodrug, which is converted in vivo to its active form, benazeprilat. "( Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.
Balfour, JA; Goa, KL, 1991
)
3.17
"Benazepril is a prodrug that, following rapid conversion to benazeprilat, is a potent nonsulfhydryl inhibitor of angiotensin-converting enzyme. "( The pharmacokinetics of benazepril relative to other ACE inhibitors.
Brady, E; Gengo, FM, 1991
)
2.03
"Benazepril hydrochloride is a new angiotensin-converting enzyme inhibitor. "( The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study.
Abraham, PA; Bennett, WM; Brachfeld, N; Goodman, RP; Hollifield, JW; Kirkendall, WM; Lasseter, KC; Leon, AS; McKenney, JM; Moser, M, 1991
)
2.08
"Benazepril HCl is an orally effective angiotensin converting enzyme (ACE) inhibitor previously shown to have significant acute hemodynamic benefits in patients with congestive heart failure. "( Chronic therapy for congestive heart failure with benazepril HCl, a new angiotensin converting enzyme inhibitor.
Boland, MJ; Cinquegrani, MP; DeSilva, J; Ghali, JK; Insel, J; Mirvis, DM; Rubin, SA; Shanes, J; Whalen, JJ, 1990
)
1.97
"Benazepril hydrochloride is a nonsulfhydryl, long-acting angiotensin-converting enzyme inhibitor that is orally effective. "( A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure.
Boland, MJ; Cinquegrani, MP; Insel, J; Mirvis, DM; Rubin, SA; Shanes, J; Whalen, JJ, 1989
)
1.97
"Benazepril appears to be an effective antihypertensive agent in hypertensive patients with moderately impaired renal function."( Effect of benazepril monotherapy in subjects with hypertension associated with renal dysfunction.
Bauer, JH; Lau, A; Reams, GP, 1989
)
1.4

Effects

Benazepril has been shown to inhibit circulating angiotensin-converting enzyme (ACE) activity in horses but the optimal dosage is unknown. It has a protective effect on mild to moderate impairment of renal function during coronary angioplasty.

ExcerptReferenceRelevance
"Benazepril has a protective effect on mild to moderate impairment of renal function during coronary angioplasty. "( Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention.
Cong, HL; He, LJ; Li, TT; Li, XM; Zhou, YJ, 2011
)
2.21
"Benazepril has been shown to inhibit circulating angiotensin-converting enzyme (ACE) activity in horses but the optimal dosage is unknown."( Attenuation of the blood pressure response to exogenous angiotensin I after oral administration of benazepril to healthy adult horses.
Afonso, T; Brown, SA; Coleman, AE; Giguère, S; Rapoport, G, 2017
)
2.11
"Benazepril has a protective effect on mild to moderate impairment of renal function during coronary angioplasty. "( Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention.
Cong, HL; He, LJ; Li, TT; Li, XM; Zhou, YJ, 2011
)
2.21
"Benazepril has two asymmetric carbon atoms, thus four optical isomers are possible, SS (benazepril), SR (CGP 14'829A), RS (CGP 42'454A), RR (CGP 42'456A)."( Antihypertensive mechanism of action of the novel angiotensin converting enzyme inhibitor benazepril. Effect on isolated vascular preparations.
Fukuda, Y; Inukai, T; Kuroda, K; Nakao, K, 1990
)
1.22

Actions

Benazepril plays an important role in down-regulating the expression of TGFbeta1 and decreasing the accumulation of ECM by blocking intrarenal renin-angiotensin system. The drug does not produce precipitous decreases in diastolic blood pressure following the initial dose, and is well tolerated by the elderly.

ExcerptReferenceRelevance
"Benazepril may cause an increase in plasma Hcy levels among patients with hypertension with low baseline Hcy levels, while effect modification by MTHFR C677T genotypes on the changes in Hcy levels in response to benazepril was not significant among patients with essential hypertension."( Elevation in Total Homocysteine Levels in Chinese Patients With Essential Hypertension Treated With Antihypertensive Benazepril.
Hsu, YH; Jiang, S; Liu, D; Pan, M; Tang, G; Venners, SA; Wang, B; Weinstock, J; Wu, S; Xu, X; Zhong, G, 2016
)
2.09
"Benazepril could inhibit intimal hyperplasia by suppressing vascular-tissue ACE."( Benazepril on tissue angiotensin-converting enzyme and cellular proliferation in restenosis after experimental angioplasty.
Li, J; Wanchun, C, 1997
)
2.46
"Benazepril could also inhibit the fibronetin and type IV collagen of ECM but was weaker in intensity."( [Contrast study on effect of shenkang injection and benazepril on human glomerular mesangial extracellular matrix].
Guo, L; Liu, Y; Mao, W, 2000
)
1.28
"Benazepril plays an important role in down-regulating the expression of TGFbeta1 and decreasing the accumulation of ECM by blocking intrarenal renin-angiotensin system."( [The effects of blocking intrarenal renin-angiotensin system on the expression of transforming growth factor-beta1 mRNA and extracellular matrix components].
Li, J; Wang, H; Zhou, C, 1999
)
1.75
"Benazepril does not produce precipitous decreases in diastolic blood pressure following the initial dose, and is well tolerated by the elderly."( The use of benazepril in hypertensive patients age 55 and over.
Gomez, HJ; Smith, WM, 1991
)
1.39

Treatment

Treatment with benazepril, valsartan, or dual blockade significantly reduced albuminuria and BP compared with placebo. Benazeprill or LEF treatment significantly prevented body weight loss and 24 h urinary protein excretion induced by diabetes.

ExcerptReferenceRelevance
"Benazepril treatment also reduced glycoprotein accumulation and fibrosis in the glomerulus and in tubular epithelial cells and inhibited nuclear factor-kappa B activation."( Postnatal renin-angiotensin system inhibition prevents renal damage from prenatal inflammation in rats.
Deng, Y; Guo, W; Han, Q; Ji, Y; Li, X; Sun, X; Wang, F; Yang, Y, 2020
)
1.28
"Benazepril or LEF treatment significantly prevented body weight loss and 24 h urinary protein excretion induced by diabetes; combined treatment with LEF and benazepril further improved these parameters compared with giving each drug alone (all p < 0.01). "( Synergistic effects of leflunomide and benazepril in streptozotocin-induced diabetic nephropathy.
Cui, ZH; Jiang, YJ; Jin, H; Jin, HF; Jin, JZ; Jin, YS; Li, C; Li, JJ; Piao, SG; Yang, CW; Zheng, HL, 2014
)
2.11
"Benazepril treatment inhibited the expression of these genes in DN but failed to rescue the same levels in the control group."( Benazepril affects integrin-linked kinase and smooth muscle α-actin expression in diabetic rat glomerulus and cultured mesangial cells.
Chi, Y; Li, Y; Liu, M; Nie, L; Niu, H; Zhang, T, 2014
)
2.57
"Benazepril treatment significantly suppressed the accumulation of AGE and expression of RAGE in the kidney of SHR."( Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu, XP; Pang, YJ; Sun, SJ; Sun, ZJ; Wang, YB; Zhao, TT; Zheng, M; Zhu, WW, 2009
)
2.52
"Benazepril pretreatment significantly improved mean arterial pressure (p<0.01), reduced left ventricular end-diastolic pressure (p<0.05), and improved both inotropic and lusitropic function of the heart (+LVdP/dt and - LVdP/dt) (p<0.05; p<0.01) as compared to IR-control."( Cardioprotective effects of benazepril, an angiotensin-converting enzyme inhibitor, in an ischaemia-reperfusion model of myocardial infarction in rats.
Arora, S; Charan Sahoo, K; Goyal, S; Kishore, K; Nag, TC; Ray, R; Singh Arya, D, 2009
)
1.37
"Benazepril treatment did not resulted in any obvious changes in EPO or Hb levels (P>0.05)."( [Effects of benazepril and valsartan on erythropoietin levels in patients with essential hypertension].
Guo, LL; Li, M; Wang, AH, 2011
)
1.47
"Benazepril treatment (10 mg/day, p.o.) reduced those changes."( Effect of benazepril on heart rate turbulence in patients with dilated cardiomyopathy.
Chen, XP; Chen, YF; Yang, XW; Yao, Z; Yun, ML; Zeng, CF; Zhong, JH, 2007
)
1.46
"Benazepril treatment is not only an effective treatment in patients with chronic renal failure."( Economic evaluation of benazepril in chronic renal insufficiency.
Mann, JF; McDonnell, J; Simeon, GP; van Hout, BA, 1997
)
1.33
"3. Treatment with benazepril inhibited the formation of AngII, reduced SBP and alleviated renal lesions in SHR compared with both untreated SHR and control WKY rats."( Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu, XP; Pang, YJ; Sun, SJ; Sun, ZJ; Wang, YB; Zhao, TT; Zheng, M; Zhu, WW, 2009
)
2.12
"Treatment with benazepril, valsartan, or dual blockade significantly reduced albuminuria and BP compared with placebo."( Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Andersen, S; Jacobsen, P; Jensen, BR; Parving, HH, 2003
)
0.66
"Treatment with benazepril or valsartan attenuates serum TGF-beta(1) levels and microalbuminuria with the combined therapy receiving the greater effect."( Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Liu, Y; Meng, QH; Wang, L; Zhu, S, 2008
)
0.69
"Treatment with benazepril sustained single nephron GFR in remnant nephrons of cats with induced renal insufficiency. "( Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency.
Brown, CA; Brown, SA; Hendi, RS; Jacobs, G; Stiles, J; Wilson, S, 2001
)
0.91

Toxicity

There were no significant differences in adverse effects between groups, with the exception of more respiratory disorders in the amlodipine/benazepril group than in the valsartan/hydrochlorothiazide group. No notable changes in body weight or heart rate were seen in either group.

ExcerptReferenceRelevance
" The mechanism of cough as an ACE inhibitor side effect is unknown; the incidence was similar to that with other ACE inhibitors."( Safety profile of benazepril in essential hypertension.
MacNab, M; Mallows, S, 1991
)
0.62
" The incidence of adverse events, particularly cough, was lower with benazepril + hydrochlorothiazide than with benazepril alone; no notable changes in body weight or heart rate were seen in either group."( Efficacy and safety of benazepril plus hydrochlorothiazide versus benazepril alone in hypertensive patients unresponsive to benazepril monotherapy.
Holwerda, K; Hoogma, RP; Huige, RC; Oldenbroek, C; Rijnierse, JM; Wester, A,
)
0.68
" The total number of patients with adverse experiences were 10 (45."( Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Aldigier, JC; Botteri, F; Mann, JF; Oddou-Stock, P; Ponticelli, C; Ruilope, LM, 2000
)
0.57
"These results indicate that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure."( Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Aldigier, JC; Botteri, F; Mann, JF; Oddou-Stock, P; Ponticelli, C; Ruilope, LM, 2000
)
0.57
" The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar."( Efficacy and safety of benazepril for advanced chronic renal insufficiency.
Chen, PY; Geng, RW; Hou, FF; Jiang, JP; Liang, M; Liu, ZR; Wang, GB; Xie, D; Zhang, GH; Zhang, WR; Zhang, X, 2006
)
0.89
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" There were no significant differences in adverse effects between groups, with the exception of more respiratory disorders in the amlodipine/benazepril group than in the valsartan/hydrochlorothiazide group (17 vs 5; P = 0 ."( Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012
)
0.79
" However, respiratory adverse events (particularly coughing) were more frequently reported in the amlodipine/benazepril group."( Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012
)
0.8
" Benazepril appeared safe in a heterogeneous population of cats."( Safety of Benazepril in 400 Azotemic and 110 Non-Azotemic Client-Owned Cats (2001-2012).
Chew, DJ; Huston, CL; Lavallee, JO; Norsworthy, GD,
)
1.44

Pharmacokinetics

The time to peak (Tmax) and the apparent elimination half-life (t1/2) for benazepril were 0. The mean values of AUC (0-4 h), Cmax and Tmax for benzepril given as combination versus given alone were 161 vs 140 ng. The absorption, bioactivation, distribution, and elimination of benazEpril and benazEPrilat have been evaluated in healthy subjects, hypertensive patients, and patients with characteristics known to alter the pharmacokinetic disposition of ACE inhibitors.

ExcerptReferenceRelevance
" The absorption, bioactivation, distribution, and elimination of benazepril and benazeprilat have been evaluated in healthy subjects, hypertensive patients, and patients with characteristics known to alter the pharmacokinetic disposition of ACE inhibitors, such as renal impairment, hepatic impairment, and advanced age."( The pharmacokinetics of benazepril relative to other ACE inhibitors.
Brady, E; Gengo, FM, 1991
)
0.83
" The time to maximum plasma concentration, tmax (0."( Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly.
Ackermann, R; Dieterle, W; Durnin, CJ; Ghose, K; Holmes, IB; Kaiser, G; McEwen, J; Richens, A, 1990
)
0.52
" The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng."( Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects.
Chan, K; Cipriano, A; John, VA; Sun, JX, 1994
)
0.8
" On average, the pharmacokinetic parameters of benazepril and benazeprilat in the patients did not differ from those in a historical control group of healthy volunteers, but intersubject variability in the AUC and half-lives of benazeprilat was greater in the patients."( Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria.
Dieterle, W; Kaiser, G; Mann, J; Schweizer, C, 1993
)
0.81
"Plasma pharmacokinetic variables of benazeprilat, the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor benazepril, were evaluated in healthy Beagles."( Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
Kaiser, G; King, JN; Mauron, C, 1995
)
0.83
"47, equivalent to a half-life for accumulation (t1/2acc) of 14."( Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
Kaiser, G; King, JN; Maurer, M; Mauron, C; Morrison, CA, 1997
)
0.53
" Based upon this study performed on normal dogs given a single dose, no pharmacokinetic advantage or disadvantage is apparent for any ACEi except captopril, which, at the dosage used, decreased ACE levels to a much lesser degree and shorter time."( Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles.
Hamlin, RL; Nakayama, T,
)
0.13
" The pharmacokinetic endpoints were plasma concentrations of benazepril and benazeprilat, and recovery of radioactivity in faeces and urine."( Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
King, JN; Maurer, M; Toutain, PL, 2003
)
0.79
" The developed assay method was successfully applied to a pharmacokinetic study in human male volunteers."( Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Inamadugu, JK; Karra, VK; Mullangi, R; Pilli, NR; Rao, JV; Vaidya, JR, 2011
)
0.6
"To compare the pharmacokinetic (PK) profiles and evaluate the PK interaction of hydrochlorothiazide (HCTZ) used alone and in combination with benazepril (BENA) or valsartan (VAL) in healthy Chinese volunteers."( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction.
Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011
)
0.8
" The apparent terminal half-life (t(1/2)) and the time to C(max) (tmax) were unchanged between the two studies."( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction.
Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011
)
0.6
"Pharmacokinetic and pharmacodynamic (PK/PD) properties of the angiotensin-converting enzyme inhibitor (ACEI) benazeprilat have not been evaluated in horses."( Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.
Ayala, N; Caballero, JMS; Castejón-Riber, C; Esgueva, M; Gómez-Díez, M; Mena-Bravo, A; Muñoz, A; Priego-Capote, F; Serrano-Rodríguez, JM, 2017
)
0.93

Compound-Compound Interactions

MMF, especially combined with benazepril, can reduce proteinuria, improve renal function, ameliorate tubulointerstitial fibrosis in 5/6 nephrectomized rats.

ExcerptReferenceRelevance
" The results of comparative trials of benazepril with propranolol and nifedipine suggest that benazepril, administered alone or with the diuretic hydrochlorothiazide, is as effective as the other antihypertensive agents alone or in combination with hydrochlorothiazide."( Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide.
DeQuattro, V, 1991
)
0.91
" Twenty-eight patients with mild to moderate hypertension were studied (clinic blood pressure > or = 160/95 mmHg), treated with benazepril alone (n = 7) or combined with hydrochlorothiazide (n = 21)."( [Comparison of clinical and ambulatory measurements of blood pressure with benazepril alone or combined with hydrochlorothiazide in hypertension].
Cocco-Guyomarch, L; Francillon, A; Le Feuvre, C; Muller, M; Peuplier, P; Poggi, L; Renucci, JF,
)
0.57
"To observe the effects of routine doses of benazepril combined with valsartan on congestive heart failure."( [Effects of benazepril combined with valsartan on congestive heart failure].
Liu, DS; Ye, JF, 2005
)
0.97
"To observe the protective effect on renal function of Chinese drugs combined with benazepril in patients with diabetic nephropathy (DN)."( [Clinical observation on treatment of diabetic nephropathy with Chinese drugs combined with benazepril].
Wang, HC; Wang, XX; Wang, YZ, 2007
)
0.79
"The treatment program of Chinese drugs combined with benazepril could obviously reduce the levels of SCr and 24 hUpro, increase CCr in patients with DN, and its effect in improving renal function is better than that of using benazepril alone."( [Clinical observation on treatment of diabetic nephropathy with Chinese drugs combined with benazepril].
Wang, HC; Wang, XX; Wang, YZ, 2007
)
0.81
" The present study was to disclose the effect of MMF combined with benazapril on delaying tubulointerstitial fibrosis and its possible mechanisms in 5/6 nephrectomized rats."( Could mycophenolate mofetil combined with benazapril delay tubulointerstitial fibrosis in 5/6 nephrectomized rats?
Liu, WH; Tang, NN; Zhang, QD, 2009
)
0.35
"MMF, especially combined with benazepril, can reduce proteinuria, improve renal function, ameliorate tubulointerstitial fibrosis in 5/6 nephrectomized rats."( Could mycophenolate mofetil combined with benazapril delay tubulointerstitial fibrosis in 5/6 nephrectomized rats?
Liu, WH; Tang, NN; Zhang, QD, 2009
)
0.64
"To compare the pharmacokinetic (PK) profiles and evaluate the PK interaction of hydrochlorothiazide (HCTZ) used alone and in combination with benazepril (BENA) or valsartan (VAL) in healthy Chinese volunteers."( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction.
Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011
)
0.8
" Overall, HCTZ alone as well as in combination with BENA and VAL was well tolerated within the scope of the current studies in Chinese health volunteers."( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction.
Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011
)
0.6
"As for CGN CKD 3 patients, treatment by Benazepril combined with wind dispelling and dampness removing Chinese herbs showed favorable renal protective effects."( [Efficiency of benazepril combined with wind dispelling and dampness removing chinese herbs on stage 3 chronic kidney disease with wind-dampness syndrome: a prospective study].
Fang, YQ; Lu, Y; Wang, YJ, 2012
)
1
"Four simple, accurate, reproducible, and selective methods have been developed and subsequently validated for the determination of Benazepril (BENZ) alone and in combination with Amlodipine (AML) in pharmaceutical dosage form."( Comparative study between univariate spectrophotometry and multivariate calibration as analytical tools for quantitation of Benazepril alone and in combination with Amlodipine.
Elaziz, OA; Farouk, M; Hemdan, A; Shehata, MA; Tawakkol, SM, 2014
)
0.81
"To study the protective effects of valsartan (Val) and benazepril, (Ben) combined with atorvastatin (Ato), on cardiorenal syndrome (CRS) in rats."( Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Chen, J; Hu, YJ; Peng, DF; Tang, SY, 2015
)
0.94
"Valsartan and benazepril, combined with atorvastatin, can have significant protective effects on cardiorenal functions of rats with CRS, with no significant difference between these two drugs."( Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Chen, J; Hu, YJ; Peng, DF; Tang, SY, 2015
)
1.05
"The aims to investigate the different protective effects of valsartan and benazepril when combined with atorvastatin in the cardio-renal functions of cardio-renal syndrome (CRS) patients."( Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS).
Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY, 2015
)
0.94
"When combined with atorvastatin, both valsartan and benazepril effectively improved the cardio-renal functions of early CRS patients."( Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS).
Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY, 2015
)
0.96
"The aim of this study was to observe the clinical efficacy of fluvastatin combined with benazepril in the treatment of patients with atrial fibrillation (AF)."( Fluvastatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation.
Jiang, L; Liang, ZG; Lin, X; Yao, H, 2016
)
0.96
"To observe the effect of moxibustion combined with benazepril on cardiac function and expression levels of myocardial interleukin-18(IL-18), phosphorylated protein kinase B(p-Akt) in rats with chronic heart failure (CHF), so as to explore its underlying mechanisms in improvement of CHF."( [Effect of moxibustion combined with benazepril on expression of IL-18 and phosphorylated protein kinase B in myocardial tissue of rats with chronic heart failure].
Gao, B; Li, QL; Ma, Q; Wang, J; Wang, W; Wang, Y; Xia, R, 2021
)
1.15
"Moxibustion combined with benazepril improves cardiac function in CHF rats, and is superior to simple moxibustion and simple benazepril in reducing IL-18 expression and increasing p-Akt expression in myocardial tissue."( [Effect of moxibustion combined with benazepril on expression of IL-18 and phosphorylated protein kinase B in myocardial tissue of rats with chronic heart failure].
Gao, B; Li, QL; Ma, Q; Wang, J; Wang, W; Wang, Y; Xia, R, 2021
)
1.19
"To observe the effects of moxibustion at bilateral Feishu (BL13) and Xinshu (BL15) combined with benazepril on myocardial cells apoptosis index, the expression levels of apoptosis-related proteins cytochrome c (Cyt-C) and apoptosis-inducing factor (AIF) in chronic heart failure (CHF) rats."( Effects of moxibustion at bilateral Feishu (BL13) and Xinshu (BL15) combined with benazepril on myocardial cells apoptosis index and apoptosis-related proteins cytochrome c and apoptosis-inducing factor in rats with chronic heart failure.
Bing, G; Jing, W; Qiang, MA; Qingling, LI; Ran, X; Wei, W; Yi, W, 2022
)
1.16
"Moxibustion at bilateral Feishu (BL13) and Xinshu (BL15) combined with benazepril could improve CHF better than moxibustion at bilateral Feishu (BL13) and Xinshu (BL15) or benazepril alone."( Effects of moxibustion at bilateral Feishu (BL13) and Xinshu (BL15) combined with benazepril on myocardial cells apoptosis index and apoptosis-related proteins cytochrome c and apoptosis-inducing factor in rats with chronic heart failure.
Bing, G; Jing, W; Qiang, MA; Qingling, LI; Ran, X; Wei, W; Yi, W, 2022
)
1.18

Bioavailability

Coadministration of benazepril with food delays absorption slightly but does not affect the ultimate bioavailability. In patients with hepatic cirrhosis, the kinetics and bioavailability were not affected. Systemic bioavailability of benzeprilat after PO benazapril was 3-4%.

ExcerptReferenceRelevance
" Coadministration of benazepril with food delays absorption slightly but does not affect the ultimate bioavailability of benazeprilat."( The pharmacokinetics of benazepril relative to other ACE inhibitors.
Brady, E; Gengo, FM, 1991
)
0.91
" In patients with hepatic cirrhosis, the kinetics and bioavailability of benazeprilat were not affected."( Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations.
Ackermann, R; Kaiser, G; Sioufi, A, 1989
)
0.74
" The absorption rate after COLON was much slower (lower Cmax and longer Tmax) compared to that after SI, and the apparent half-life (1."( Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers.
Barr, WH; Buch, A; Chan, KK; Glazer, RD; John, VA, 1994
)
0.54
" These results suggest that the combination of an ARB and an ACEI exerts an additive inhibitory effect, presumably through an increase in production and bioavailability of NO from the endothelium."( Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
Katayama, S; Morita, T; Yagi, S, 2004
)
0.32
" The method can be used to assess the bioavailability and pharmacokinetics of the drug."( Simultaneous determination of benazepril hydrochloride and benazeprilat in plasma by high-performance liquid chromatography/electrospray-mass spectrometry.
Chen, B; Cheng, Z; Xiao, W; Yao, S, 2005
)
0.62
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"BENA decreased the bioavailability of HCTZ in Chinese healthy volunteers while VAL greatly increased the concentration of HCTZ in plasma during coadministration."( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction.
Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011
)
0.6
" Systemic bioavailability of benazeprilat after PO benazepril was 3-4%."( Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.
Ayala, N; Caballero, JMS; Castejón-Riber, C; Esgueva, M; Gómez-Díez, M; Mena-Bravo, A; Muñoz, A; Priego-Capote, F; Serrano-Rodríguez, JM, 2017
)
1.01
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The antihypertensive effect of benazepril was observed as early as 30 min after a single dose. By increasing the dosage to 20 mg, a further 5 patients became responder. No significant change was obtained in GFR after a 28-day period of dosing with tepox.

ExcerptRelevanceReference
" The antihypertensive effect of benazepril was observed as early as 30 min after a single dose, and those effects during consecutive dosing were also sustained for 24 h with a lesser diurnal variation in blood pressure (BP)."( Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function.
Gotoh, E; Ishii, M; Minamisawa, K; Minamisawa, M; Shionoiri, H; Sugimoto, K; Takasaki, I; Ueda, S, 1992
)
0.83
"The dose-response curve for benazepril, a new angiotensin-converting enzyme inhibitor, has been established from a systematic series of controlled clinical studies in patients with mild to moderate essential hypertension."( Dose-response studies with benazepril in mild to moderate hypertension.
Gomez, HJ, 1991
)
0.87
" Severe hepatic impairment slows conversion of benazepril to benazeprilat but does not affect the overall bioavailability of benazeprilat; thus dosage adjustment is not necessary in the hepatically impaired population."( The pharmacokinetics of benazepril relative to other ACE inhibitors.
Brady, E; Gengo, FM, 1991
)
0.85
" The 20 mg dosage of benazepril lowered blood pressure to a degree equal to that of 25 mg hydrochlorothiazide: -12."( The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study.
Abraham, PA; Bennett, WM; Brachfeld, N; Goodman, RP; Hollifield, JW; Kirkendall, WM; Lasseter, KC; Leon, AS; McKenney, JM; Moser, M, 1991
)
0.95
" Thus, there seems to be no need for dosage adjustment of benazepril hydrochloride in patients suffering from cirrhosis of the liver."( The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride.
Ackermann, R; Defalco, A; Gschwind, HP; Holmes, IB; James, IM; Kaiser, G; McIntyre, N; Sprengers, D, 1990
)
0.76
" Its onset and duration of action and the dose-response relationship of its antihypertensive effect have been evaluated."( Definition of the effective dose of the converting-enzyme inhibitor benazepril.
Whalen, JJ, 1989
)
0.51
" Benazepril doubled the urinary excretion of sodium over the first 4 hours after dosing whilst on the low salt diet; the equivalent increase during salt loading was approximately 20%."( Effect of salt balance on the renal and hemodynamic actions of benazepril in normal men.
Fuller, GN; Lant, AF; Noormohamed, FH, 1989
)
1.43
" In the clinical development of an antihypertensive drug, the earlier use of such within-patient studies, with the random insertion of one placebo period between the active periods, should help in the dose-response curve search."( Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension.
Bellet, M; Corvol, P; Guyene, TT; Ménard, J; Sassano, P; Serrurier, D, 1989
)
0.28
" The drug disposition did not change during repeated oral dosing and only small accumulation of the metabolite occurred."( Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.
Ackermann, R; Brechbühler, S; Dieterle, W; Kaiser, G,
)
0.37
"5 and 2 h after dosing (median 1 h)."( Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria.
Dieterle, W; Kaiser, G; Mann, J; Schweizer, C, 1993
)
0.55
" In pts with DBP > 90 mmHg after 4 weeks, the dosage of trial medication was doubled and continued for further 4 weeks."( [Influence of angiotensin I converting enzyme inhibitors on selected parameters of zinc metabolism].
Peczkowska, M, 1996
)
0.29
" The age related differences in kinetics and dynamics following multiple dosing are quantitatively similar to those obtained with single doses."( A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril.
Elliott, HL; Hughes, DM; Macdonald, NJ; Reid, JL, 1993
)
0.49
" Both the low and high dosage of benazepril resulted in a significant decrease in blood pressure (31 and 44 mm Hg, respectively)."( Benazepril on tissue angiotensin-converting enzyme and cellular proliferation in restenosis after experimental angioplasty.
Li, J; Wanchun, C, 1997
)
2.02
" Drugs or vehicle (V) were administered subcutaneously for 6 weeks with dosing initiated 1 week after renal mass reduction."( Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure.
Cohen, DS; Dotson, RA; Graybill, SR; Mathis, JE; Wosu, NJ, 1998
)
0.3
"The pharmacokinetics of benazepril, enalapril, and their active metabolites (benazeprilat and enalaprilat) were compared after a single administration of each product by the oral route at the recommended dosage (0."( Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.
Concordet, D; Laroute, V; Lefebvre, HP; Toutain, PL,
)
0.66
"A micro-bore liquid chromatographic method was developed for the simultaneous determination of benazepril hydrochloride and hydrochlorothiazide in pharmaceutical dosage forms."( Simultaneous determination of benazepril hydrochloride and hydrochlorothiazide by micro-bore liquid chromatography.
Panderi, IE; Parissi-Poulou, M, 1999
)
0.81
"A second-order derivative spectrophotometric method for the simultaneous determination of benazepril hydrochloride and hydrochlorothiazide in pharmaceutical dosage forms is described."( Simultaneous determination of benazepril hydrochloride and hydrochlorothiazide in tablets by second-order derivative spectrophotometry.
Panderi, IE, 1999
)
0.81
"Three sensitive and accurate methods are presented for the determination of benazepril in its dosage forms."( Spectrophotometric methods for the determination of benazepril hydrochloride in its single and multi-component dosage forms.
Abdine, HH; El-Yazbi, FA; Shaalan, RA, 1999
)
0.78
" Benazepril seemed to have a high safety, and the adjustment of dosage regimen might not be needed in dogs with mild to moderate renal function impairment because the drug was excreted both from the kidneys and liver."( Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
Eguchi, T; Kitagawa, H; Kitoh, K; Kondo, M; Nakano, M; Ohba, Y; Sasaki, Y, 2000
)
1.45
"A gradient liquid chromatographic (LC) method has been developed for the determination and purity evaluation of benazepril hydrochloride in bulk and pharmaceutical dosage forms."( A validated method for the determination and purity evaluation of benazepril hydrochloride in bulk and in pharmaceutical dosage forms by liquid chromatography.
Radhakrishna, T; Rao, DS; Reddy, GO; Vyas, K, 2000
)
0.76
" The proposed method was applied successfully to the determination of benazepril in its dosage forms, the percentage recoveries +/- SD (n = 9) were 99."( Spectrophotometric determination of benazepril in tablets.
Abounassif, MA; Al-Zaagi, IA; Belal, F,
)
0.64
" Results obtained for the proposed method when applied to the determination of both compounds in dosage forms were in good agreement with those obtained using reference methods."( Voltammetric determination of benazepril and ramipril in dosage forms and biological fluids through nitrosation.
Abounassif, MA; Al-Zaagi, IA; Belal, F,
)
0.42
" Losartan improved the shifted circadian BP rhythm towards the active phase in a dose-dependent manner, whereas the improvement caused by 1 and 3 mg/day of benazepril was less effective than the same dosage of losartan."( Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP.
Hayasaki-Kajiwara, Y; Iwasaki, T; Nakajima, M; Naya, N; Shimamura, T, 2002
)
0.82
"Both SKI and benazepril could inhibit the proliferation of human MC, but in equal dosage consistency, SKI showed a better inhibitory effect than that of benazepril."( [Serological study on inhibitory function of shenkang injection on glomerular mesangial cell].
Guo, LZ; Mao, W; Wang, HM, 2001
)
0.68
" at the same dosage for 6 weeks in three crossover periods each separated by a 2-week placebo wash-out period (3x3 latin square)."( Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2003
)
0.72
" The simple physical model proposed in this report was found to be useful in predicting the dissolution stability of the dosage form."( Correlation and prediction of moisture-mediated dissolution stability for benazepril hydrochloride tablets.
Comfort, A; Fleres, S; Li, S; Royce, A; Wei, B, 2004
)
0.55
" All of them were treated orally with benazepril at a single daily fixed dosage of 10 mg for 15 consecutive days."( The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor.
Chen, C; Hsu, YH; Jiang, S; Niu, T; Peng, S; Xing, H; Xu, X; Zhang, Y, 2004
)
0.59
" A total of 410 hypertensive patients recruited from 344 nuclear families were treated orally with benazepril at a daily dosage of 10 mg for 15 consecutive days."( A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study.
Chen, C; Hsu, YH; Jiang, S; Niu, T; Peng, S; Wang, X; Xing, H; Xu, X; Zhang, Y, 2005
)
0.55
" No significant change was obtained in GFR after a 28-day period of dosing with tepoxalin and benazepril together."( Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor.
Debailleul, M; Desfontis, JC; Fusellier, M; Gautier, F; Gogny, M; Madec, S; Marescaux, L, 2005
)
0.55
" An inverse dose-response relation between alcohol drinking and (deltaSBP) as well as (deltaDBP) was observed either."( [Influence of alcohol consumption on effectiveness of antihypertensive in male patients with essential hypertension].
Huang, AQ; Jin, YT; Li, D; Peng, SJ, 2005
)
0.33
" Patients received open-label treatment with a conventional dosage of benazepril (10 mg/d), individual uptitration of benazepril (median 20 mg/d; range 10 to 40), a conventional dosage of losartan (50 mg/d), or individual uptitration of losartan (median 100 mg/d; range 50 to 200)."( Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
Chen, PY; Guo, ZJ; Hou, FF; Jiang, JP; Liang, M; Xie, D; Zhang, WR; Zhang, X, 2007
)
0.79
"Treatment regimens that require fewer dosage units and less frequent dosing to decrease the complexity and cost of care are among the strategies recommended to improve compliance with antihypertensive therapy."( Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.
Dickson, M; Plauschinat, CA, 2008
)
0.56
" Conventional treatment for lowering blood glucose was given to both groups, but to the control group 10 mg benazepril was given orally once a day additionally, while to those in the treatment group the same dosage of benazepril po."( [Effect of treatment in 39 patients with diabetic nephropathy by safflor yellow and benazepril in combination].
Chen, ZQ; Guo, DZ; Wang, YH, 2008
)
0.78
"A rapid, precise, specific, and accurate ultra performance liquid chromatography (UPLC) method has been developed and subsequently validated for simultaneous determination of amlodipine present as amlodipine basylate (AB) and benazepril hydrochloride (BH) in capsule dosage form."( Simultaneous determination of amlodipine besylate and benazepril hydrochloride in pharmaceutical dosage form by LC.
Farooqui, MN; Kasawar, GB, 2009
)
0.79
"Hypertensive patients from Huoqiu County and Yuexi County of Anhui Province received daily treatment with an oral dosage of 10 mg benazepril for 15 days."( E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients.
Hong, XM; Huo, Y; Li, JP; Xing, HX; Xu, XP; Zhang, Y, 2009
)
0.77
"Twenty canines were randomly divided into 3 groups: (1) Sham-operated group without RAP; (2) AF group: AF established by RAP at 600 beats per minute for 6 weeks; (3) Benazepril group: benazepril was dosed from 1 week pre-pacing to 6 weeks post-pacing."( [Effect of benazepril on atrial cytoskeleton remodeling in the canine atrial fibrillation models].
Bai, B; Huang, YL; Liu, L; Qu, XF; Yu, Y, 2009
)
0.94
" In this study, we conducted an investigation of the combined effects of 5, 10-methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase (MS) A2756G polymorphisms on baseline blood pressure (BP) and BP response to antihypertensive Benazepril treatment in 823 Chinese hypertensive patients with a fixed daily dosage of 10 mg for 15 consecutive days."( Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients.
Jiang, S; Venners, SA; Wang, X; Xing, H; Xu, X; Yu, Y; Zhang, Y, 2011
)
0.78
" In the two groups the patients with SeDBP ≥ 90 mm Hg were doubled the dosage of the initial regimen at the end of 4-week treatment for additional 4 weeks, and the patients with SeDBP < 90 mm Hg remained the initial regimen for additional 4 weeks."( [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].
Fan, CM; Gao, MM; Li, CX; Li, YQ; Li, YS; Lu, XL; Pang, HM; Tao, YK; Wang, L; Wang, XW; Wang, YN; Yan, LR, 2011
)
0.72
" It was concluded when the similar SBP reduction, RAAS inhibition and clock gene profile were achieved with optimal dose of benazepril, morning versus evening dosing of benazepril has the same renoprotection effects."( Effects of chronotherapy of benazepril on the diurnal profile of RAAS and clock genes in the kidney of 5/6 nephrectomy rats.
Chen, WL; Huang, XM; Mei, QH; Peng, CX; Yuan, JP; Zeng, XR, 2013
)
0.89
" At 4 weeks, the dosage of Benazepril was titrated up to 20 mg if the diastolic blood pressure (DBP) remained ≥ 90 mmHg."( Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension.
An, WS; Chen, GH; Chen, T; Li, JD; Yang, TS; Zhang, XX; Zhong, ZY, 2013
)
0.94
"Four simple, accurate, reproducible, and selective methods have been developed and subsequently validated for the determination of Benazepril (BENZ) alone and in combination with Amlodipine (AML) in pharmaceutical dosage form."( Comparative study between univariate spectrophotometry and multivariate calibration as analytical tools for quantitation of Benazepril alone and in combination with Amlodipine.
Elaziz, OA; Farouk, M; Hemdan, A; Shehata, MA; Tawakkol, SM, 2014
)
0.81
" Moreover, the methods were successfully applied for the determination of HCZ and BZ and AM in pure form and pharmaceutical dosage forms."( Simultaneous determination of hydrochlorothiazide and benazepril hydrochloride or amiloride hydrochloride in presence of hydrochlorothiazide impurities: chlorothiazide and salamide by HPTLC method.
Abdelaleem, EA; Draz, ME; Naguib, IA; Zaazaa, HE, 2015
)
0.67
" The analysis results prove to be valid for analysis of the two active ingredients in raw materials and pharmaceutical dosage form through handling UV spectral data in range (220-350 nm)."( Linear support vector regression and partial least squares chemometric models for determination of Hydrochlorothiazide and Benazepril hydrochloride in presence of related impurities: a comparative study.
Abdelaleem, EA; Draz, ME; Naguib, IA; Zaazaa, HE, 2014
)
0.61
" A mechanism-based pharmacokinetic/pharmacodynamic model, which includes the periodic nature of RA, AII, and ALD during placebo treatment and the subsequent changes in dynamics following repeated dosing with benazepril, was developed."( Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
Danhof, M; Fink, M; Giraudel, JM; Mochel, JP; Peyrou, M; Soubret, A, 2015
)
0.8
" Although several experiments have pointed out that efficacy of ACE inhibitors depends on the time of administration, little attention is paid to the optimum time of dosing of these medications."( Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned?
Danhof, M; Mochel, JP, 2015
)
0.42
"Three simple, selective, and accurate spectrophotometric methods have been developed and then validated for the analysis of Benazepril (BENZ) and Amlodipine (AML) in bulk powder and pharmaceutical dosage form."( Development and validation of different methods manipulating zero order and first order spectra for determination of the partially overlapped mixture benazepril and amlodipine: A comparative study.
Hemdan, A, 2016
)
0.84
"Benazepril has been shown to inhibit circulating angiotensin-converting enzyme (ACE) activity in horses but the optimal dosage is unknown."( Attenuation of the blood pressure response to exogenous angiotensin I after oral administration of benazepril to healthy adult horses.
Afonso, T; Brown, SA; Coleman, AE; Giguère, S; Rapoport, G, 2017
)
2.11
"With a great quantity of solid dosage tested by dissolution technology, developing a rapid and sensitive method to access the content of drug within dissolution media is highly desired by analysts and scientists."( Rapid analysis of drug dissolution by paper spray ionization mass spectrometry.
He, L; Lin, L; Liu, N; Liu, Y; Zhou, YN, 2017
)
0.46
" The method was applied to the assay of BNZ in combined dosage form with no interference from other ingredients."( Kinetic Profiling of the Hydrolytic Reaction of Benazepril: Metabolic Pathway Simulation.
Hemdan, A; Michael, AM, 2018
)
0.74
"Horses with mitral valve (MR) and/or aortic valve regurgitation (AR) received oral benazepril (n = 6) at a dosage of 1 mg/kg q 12 h or a placebo (n = 5) for 28 days."( Preliminary investigation of orally administered benazepril in horses with left-sided valvular regurgitation.
Afonso, T; Barba, M; Barton, MH; Brown, SA; Coleman, AE; Dembek, KA; Giguère, S; Rapoport, G; Toribio, RE, 2018
)
0.96
"0 mg/kg benazepril dosed SID."( Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs.
Christinaz, C; Hornfeld, J; King, JN; Strehlau, G, 2018
)
1.32
" Cardiac endpoint was defined as cardiac death or euthanasia, recurrence of pulmonary edema, necessity for nonauthorized cardiac drug(s) or a furosemide dosage >8 mg/kg/d."( Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
Atkins, CE; Blondel, T; Coffman, M; Feng, S; Garelli-Paar, C; Guillot, E; Heartsill, S, 2021
)
0.93
" Blood samples were collected at serial time intervals after benazepril dosing to measure plasma benazeprilat (active metabolite of benazepril) and serum RAAS biomarkers."( Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs.
Domenig, O; Gabriel, V; Guillot, E; Iennarella-Servantez, CA; Mochel, JP; Smith, JS; Sotillo, S; Ward, JL; Yuan, L, 2023
)
1.49
"Personalized dosing regimens have great potential to improve the standard level of care from "one-fits-all" to the "right dose, to the right patient at the right time"."( Development of a Digital Interface for Personalized Dosing in Renal Impaired Patients: A Case-Study Using the ACE-Inhibitor Benazepril.
Paudel, A; Pinto, JT; Reinisch, V, 2023
)
1.12
"Development of a digital interface that can inform healthcare professionals on the dosing of an ACE inhibitor on an individual basis."( Development of a Digital Interface for Personalized Dosing in Renal Impaired Patients: A Case-Study Using the ACE-Inhibitor Benazepril.
Paudel, A; Pinto, JT; Reinisch, V, 2023
)
1.12
"The use of the models via a practical user interface can help inform clinical decisions and design optimal dosing based on the individual anthropometric characteristics and stage of renal impairment."( Development of a Digital Interface for Personalized Dosing in Renal Impaired Patients: A Case-Study Using the ACE-Inhibitor Benazepril.
Paudel, A; Pinto, JT; Reinisch, V, 2023
)
1.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitorAn EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
benzazepineA group of two-ring heterocyclic compounds consisting of a benzene ring fused to an azepine ring.
dicarboxylic acid monoesterA monoester of a dicarboxylic acid.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
lactamCyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
EWS/FLI fusion proteinHomo sapiens (human)Potency22.84650.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Angiotensin-converting enzyme Homo sapiens (human)IC50 (µMol)0.00170.00010.533610.0000AID39767
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)0.10470.00001.612910.0000AID1231572; AID37781; AID763534
Angiotensin-converting enzymeRattus norvegicus (Norway rat)IC50 (µMol)0.00170.00090.33223.0300AID38882
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (72)

Processvia Protein(s)Taxonomy
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (98)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID38882In vitro inhibitory activity against Angiotensin I converting enzyme1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID763534Inhibition of rabbit lung ACE assessed as hydrolysis of hippuryl-histidyl-leucine to hippuric acid and histidyl-leucine after 30 mins2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors.
AID212097Tested for 50% inhibition of thromboxane synthase (TxS) in human platelets (in vitro); Not active1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Dual angiotensin converting enzyme/thromboxane synthase inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID174577Maximal changes in blood pressure recorded during the 4 day test period in spontaneous hypertensive rats, at 3 mg/kg peroral dose1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1231572Inhibition of rabbit lung ACE assessed as hippuryl-histidyl-leucine hydrolysis after 30 mins by colorimetric method2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors.
AID38402Compound was tested for plasma inhibition of Angiotensin I converting enzyme activity in the conscious rat. Expressed as Inhibition of AI pressor response at 1 hr at a dose of 10 mg/kg po1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
AID56381In vivo inhibitory activity against Angiotensin I pressor response in normotensive dog after peroral administration1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID38708Compound was tested for plasma inhibition of Angiotensin I converting enzyme activity in the conscious rat. Expressed as Inhibition of AI pressor response at 6 hr at a dose of 10 mg/kg po1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID38569Compound was tested for plasma inhibition of Angiotensin I converting enzyme activity in the conscious rat. Expressed as Inhibition of AI pressor response at 4 hr at a dose of 10 mg/kg po1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID37781Tested for 50% inhibition of Angiotensin converting enzyme(ACE) obtained from rabbit lung (in vitro)1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Dual angiotensin converting enzyme/thromboxane synthase inhibitors.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID763533Cytotoxicity against human A549 cells assessed as cell survival after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID456232Activity at human recombinant CES1 expressed in baculovirus-infected Spodoptera frugiperda Sf21 cells assessed as substrate hydrolysis by fluorescence assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID5985271-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID599064Plasma protein binding in human2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID39767Inhibitory activity against angiotensin I converting enzyme (ACE)2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID5985261-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID38424Compound was tested for plasma inhibition of Angiotensin I converting enzyme activity in the conscious rat. Expressed as Inhibition of AI pressor response at 2 hr at a dose of 10 mg/kg po1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID763532Cytotoxicity against HEK293 cells assessed as cell survival after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID182947In vivo inhibitory activity against Angiotensin I pressor response in normotensive rats after peroral administration1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345457Human Angiotensin-converting enzyme (M2: Angiotensin-converting (ACE and ACE2))1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (549)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (4.55)18.7374
1990's143 (26.05)18.2507
2000's221 (40.26)29.6817
2010's138 (25.14)24.3611
2020's22 (4.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 88.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index88.12 (24.57)
Research Supply Index6.73 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index168.85 (26.88)
Search Engine Supply Index2.13 (0.95)

This Compound (88.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials230 (37.77%)5.53%
Reviews26 (4.27%)6.00%
Case Studies34 (5.58%)4.05%
Observational1 (0.16%)0.25%
Other318 (52.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (43)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of 10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules in Healthy Adult Male Volunteers Under Non-fasting (Fed) Conditions [NCT01155908]Phase 148 participants (Actual)Interventional2005-04-30Completed
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Benazepril (ATC N° C09AA07) in the Treatment of Persistent Renal Dysfunction in Pre-eclamptic Women [NCT01095939]Phase 3120 participants (Actual)Interventional2010-04-30Completed
Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome [NCT00309257]Phase 29 participants (Actual)Interventional2004-01-31Completed
Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) [NCT04937907]Phase 250 participants (Anticipated)Interventional2021-09-08Recruiting
Early Nephropathy Study in Diabetes With Inhibitory Renin-Angiotensin-Aldosterone System Therapy (END-IT) [NCT00907374]46 participants (Actual)Interventional2005-07-31Completed
Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria [NCT01375322]Phase 4226 participants (Actual)Interventional2007-06-30Completed
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of 10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules in Healthy Adult Male Volunteers Under Fasting Conditions [NCT01155895]Phase 154 participants (Actual)Interventional2004-03-31Completed
A Relative Bioavailability Study of 40 mg Benazepril Hydrochloride Tablets Under Non-Fasting Conditions [NCT00836537]Phase 140 participants (Actual)Interventional2001-03-31Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Single-Dose Food in Vivo Bioequivalence Study of Benazepril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Lotensin HCT® Tablets (20 mg/25 mg; Novartis) in Healthy Volunteers [NCT00649038]Phase 124 participants (Actual)Interventional2002-12-31Completed
Single Dose Two-Way Crossover Fasted Bioequivalence Study of Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets in Healthy Volunteers [NCT00778726]42 participants (Actual)Interventional2004-09-30Completed
Effects of Benazepril,Valsartan or Combination of Both on Residual Renal Function in Peritoneal Dialysis Patients [NCT00721773]200 participants (Actual)Interventional2008-09-30Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Benazepril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Lotensin HCT® Tablets (20 mg/25 mg; Novartis) in Healthy Volunteers [NCT00649597]Phase 156 participants (Actual)Interventional2002-11-30Completed
Single Dose Two-Way Crossover Fed Bioequivalence Study of Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets in Healthy Volunteers [NCT00778674]30 participants (Actual)Interventional2004-10-31Completed
A Multicenter, Group Study to Evaluate the Safety and Efficacy of Amlodipine and Benazepril Administered in Combination Compared to Amlodipine Monotherapy in Hypertensive Patients Not Adequately Controlled With Amlodipine Alone [NCT00171366]Phase 31,422 participants (Actual)Interventional2004-07-31Completed
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension [NCT00170950]Phase 311,506 participants (Actual)Interventional2003-10-31Terminated(stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.)
Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy [NCT01917149]Phase 4480 participants (Actual)Interventional2005-03-31Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Amlodipine and Benazepril HCl Capsules (10 mg/20 mg; Mylan) to Lotrel® Capsules (10 mg/20 mg; Novartis) in Healthy Volunteers [NCT00649519]Phase 154 participants (Actual)Interventional2004-05-31Completed
Single-Dose Food in Vivo Bioequivalence Study of Amlodipine and Benazepril HCl Capsules (10 mg/20 mg; Mylan) to Lotrel® Capsules (10 mg/20 mg; Novartis) in Healthy Volunteers [NCT00649402]Phase 164 participants (Actual)Interventional2004-05-31Completed
Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency [NCT00630708]309 participants (Anticipated)Interventional2008-02-29Terminated(stopped due to Significant differences observed between groups.)
A Randomized, Two-way Crossover, Single-dose, Open-label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Benazepril HCl (40 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Lotensin®, N [NCT00836576]Phase 140 participants (Actual)Interventional2001-02-28Completed
A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension [NCT00185120]Phase 4152 participants Interventional2005-09-30Completed
A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy [NCT00234871]Phase 4357 participants (Actual)Interventional2004-01-31Completed
Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus [NCT00136773]Phase 4332 participants (Actual)Interventional2003-04-30Completed
A 6-Week Multi-center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension [NCT00136851]Phase 4259 participants (Actual)Interventional2004-12-31Completed
A Prospective, Randomized, Probe Trial to Evaluate Whether, at Comparable Blood Pressure Control, Combined Therapy With the ACEI Benazepril and the ARB Valsartan, Reduces the Incidence of Microalbuminuria More Effectively Than BEN or VAL Alone in Hyperten [NCT00503152]Phase 3612 participants (Actual)Interventional2007-05-31Completed
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study [NCT01669434]Phase 4291 participants (Actual)Interventional2015-06-01Completed
A Prospective, Randomized, Probe Trial to Evaluate Whether,at Comparable Blood Pressure Control,Combined Therapy With ACEI BEN and ARB VAL Reduces Progression to ESRD More Effectively Than BEN or VAL Alone in High Risk Patients With Type 2 Diabetes and Ov [NCT00494715]Phase 3102 participants (Actual)Interventional2007-05-31Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]Phase 310,251 participants (Actual)Interventional1999-09-30Completed
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension [NCT00139555]Phase 4125 participants (Actual)Interventional2004-07-31Completed
[NCT00270426]0 participants InterventionalTerminated
[NCT00338091]0 participants Interventional2002-01-31Terminated
An Open-label Randomized, Single Dose, Two Way Crossover Oral Bioequivalence Study of Amlodipine Besylate/Benazepril HCl Capsules of Dr. Reddy's With Lotrel® Capsules of Novartis in Human Subjects Under Fed Conditions [NCT01505998]Phase 149 participants (Actual)Interventional2007-03-31Completed
An Open-label Randomized, Single Dose, Two Way Crossover Oral Bioequivalence Study of Amlodipine Besylate/Benazepril HCl Capsules of Dr. Reddy's With Lotrel® Capsules of Novartis in Human Subjects Under Fasting Conditions. [NCT01506011]Phase 150 participants (Actual)Interventional2007-03-31Completed
A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension [NCT01234922]Phase 26 participants (Actual)Interventional2011-02-28Terminated(stopped due to slow accrual)
Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function. [NCT01603940]Phase 430 participants (Actual)Interventional2012-05-31Completed
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]Phase 42,414 participants (Anticipated)Interventional2020-04-30Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
A Randomized, Multicenter, Study to Determine the Efficacy and Safety of Amlodipine/Benazepril Hydrochloride Versus Enalapril in the Treatment of Hypertension in an African-American Population With Type 2 Diabetes [NCT00367978]Phase 4275 participants (Actual)Interventional2001-12-31Completed
Efficacy and Safety of the Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Benazepril [NCT00367094]Phase 3296 participants Interventional2006-07-31Completed
A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE [NCT04486118]Phase 236 participants (Anticipated)Interventional2021-10-01Recruiting
Demonstrated Study on Children Henoch-Schönlein Purpura Nephritis With Multistep Treatment of Traditional Chinese Medicine Combined Disease and Syndrome Differentiation [NCT03591471]Phase 1/Phase 2500 participants (Anticipated)Interventional2014-09-30Recruiting
Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fed Conditions. [NCT00835367]Phase 168 participants (Actual)Interventional2004-03-31Completed
Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fasting Conditions. [NCT00834977]Phase 148 participants (Actual)Interventional2004-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000620 (6) [back to overview]Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00170950 (3) [back to overview]Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event
NCT00170950 (3) [back to overview]Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke
NCT00170950 (3) [back to overview]Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event
NCT00834977 (9) [back to overview]AUC0-inf - Amlodipine
NCT00834977 (9) [back to overview]AUC0-t - Amlodipine
NCT00834977 (9) [back to overview]Cmax - Benazeprilat
NCT00834977 (9) [back to overview]Cmax - Benazepril
NCT00834977 (9) [back to overview]Cmax - Amlodipine
NCT00834977 (9) [back to overview]AUC0-t - Benazepril
NCT00834977 (9) [back to overview]AUC0-t - Benazaprilat
NCT00834977 (9) [back to overview]AUC0-inf - Benazeprilat
NCT00834977 (9) [back to overview]AUC0-inf - Benazepril
NCT00835367 (9) [back to overview]Cmax - Amlodipine
NCT00835367 (9) [back to overview]Cmax - Benazeprilat
NCT00835367 (9) [back to overview]Cmax - Benazepril
NCT00835367 (9) [back to overview]AUC0-inf - Benazepril
NCT00835367 (9) [back to overview]AUC0-inf - Amlodipine
NCT00835367 (9) [back to overview]AUC0-inf - Benazeprilat
NCT00835367 (9) [back to overview]AUC0-t - Amlodipine
NCT00835367 (9) [back to overview]AUC0-t - Benazepril
NCT00835367 (9) [back to overview]AUC0-t - Benazeprilat
NCT00907374 (4) [back to overview]Endothelial Dysfunction
NCT00907374 (4) [back to overview]Estimated Glomerular Filtration Rate
NCT00907374 (4) [back to overview]Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio
NCT00907374 (4) [back to overview]Carotid Artery Intima Thickness
NCT01234922 (1) [back to overview]Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter
NCT01603940 (5) [back to overview]Endothelial Function
NCT01603940 (5) [back to overview]Vascular Stiffness
NCT01603940 (5) [back to overview]Diastolic Blood Pressure
NCT01603940 (5) [back to overview]Vascular Stiffness by Augmentation Index
NCT01603940 (5) [back to overview]Systolic Blood Pressure
NCT01669434 (6) [back to overview]Postoperative Hypotension
NCT01669434 (6) [back to overview]Postoperative Hypertension
NCT01669434 (6) [back to overview]Older Age Subgroup
NCT01669434 (6) [back to overview]Number of Participants With Interoperative Hypotension
NCT01669434 (6) [back to overview]Low Blood Pressure Subgroup
NCT01669434 (6) [back to overview]Acute Renal Failure

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control36
BP Trial: Standard Control62

[back to top]

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control391
Glycemia Trial: Standard Control327

[back to top]

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control503
Glycemia Trial: Standard Control543

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control208
BP Trial: Standard Control237

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate291
Lipid Trial: Placebo310

[back to top]

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate641
Lipid Trial: Placebo667

[back to top]

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event

Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]

InterventionPercentage of Patients with an Event (Number)
Benazepril/Amlodipine8.6
Benazepril/Hydrochlorothiazide10.3

[back to top]

Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

InterventionPercentage of Patients with an Event (Number)
Benazepril/Amlodipine5.0
Benazepril/Hydrochlorothiazide6.3

[back to top]

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event

CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

InterventionPercentage of Patients with an event (Number)
Benazepril/Amlodipine9.6
Benazepril/Hydrochlorothiazide11.8

[back to top]

AUC0-inf - Amlodipine

Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated) (NCT00834977)
Timeframe: Blood samples collected over 168 hour period

Interventionpg*h/mL (Mean)
Amlodipine Benazepril365612.90
Lotrel®366523.24

[back to top]

AUC0-t - Amlodipine

Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant) (NCT00834977)
Timeframe: Blood samples collected over 168 hour period

Interventionpg*h/mL (Mean)
Amlodipine Benazepril328249.86
Lotrel®331782.17

[back to top]

Cmax - Benazeprilat

Cmax - Maximum observed concentration (NCT00834977)
Timeframe: Blood samples collected over 36 hour period

Interventionng/mL (Mean)
Amlodipine Benazepril378.27
Lotrel®397.50

[back to top]

Cmax - Benazepril

Bioequvialence based on Cmax - Maximum observed concentration (NCT00834977)
Timeframe: Blood samples collected over 36 hour period

Interventionng/mL (Mean)
Amlodipine Benazepril330.93
Lotrel®340.57

[back to top]

Cmax - Amlodipine

Bioequivalence based on Cmax - Maximum observed concentration (NCT00834977)
Timeframe: Blood samples collected over 168 hour period

Interventionpg/mL (Mean)
Amlodipine Benazepril6299.49
Lotrel®6185.06

[back to top]

AUC0-t - Benazepril

Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant) (NCT00834977)
Timeframe: Blood samples collected over 36 hour period

Interventionng*h/mL (Mean)
Amlodipine Benazepril241.65
Lotrel®250.13

[back to top]

AUC0-t - Benazaprilat

AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant) (NCT00834977)
Timeframe: Blood samples collected over 36 hour period

Interventionng*h/mL (Mean)
Amlodipine Benazepril1981.29
Lotrel®1990.26

[back to top]

AUC0-inf - Benazeprilat

AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated) (NCT00834977)
Timeframe: Blood samples collected over 36 hour period

Interventionng*h/mL (Mean)
Amlodipine Benazepril2027.53
Lotrel®2033.12

[back to top]

AUC0-inf - Benazepril

Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated) (NCT00834977)
Timeframe: Blood samples collected over 36 hour period

Interventionng*h/mL (Mean)
Amlodipine Benazepril245.15
Lotrel®253.21

[back to top]

Cmax - Amlodipine

Bioequivalence based on Cmax - Maximum observed concentration (NCT00835367)
Timeframe: Blood samples collected over 168 hour period

Interventionpg/mL (Mean)
Amlodipine Benazepril5621.36
Lotrel®5536.86

[back to top]

Cmax - Benazeprilat

Cmax - Maximum observed concentration (NCT00835367)
Timeframe: Blood samples collected over 36 hour period

Interventionng/mL (Mean)
Amlodipine Benazepril226.79
Lotrel®235.85

[back to top]

Cmax - Benazepril

Bioequivalence based on Cmax - Maximum observed concentration (NCT00835367)
Timeframe: Blood samples collected over 36 hour period

Interventionng/mL (Mean)
Amlodipine Benazepril92.13
Lotrel®101.55

[back to top]

AUC0-inf - Benazepril

Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated) (NCT00835367)
Timeframe: Blood samples collected over 36 hour period

Interventionng*h/mL (Mean)
Amlodipine Benazepril201.36
Lotrel®194.76

[back to top]

AUC0-inf - Amlodipine

Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated) (NCT00835367)
Timeframe: Blood samples collected over 168 hour period

Interventionpg*h/mL (Mean)
Amlodipine Benazepril370735.08
Lotrel®363080.38

[back to top]

AUC0-inf - Benazeprilat

AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated) (NCT00835367)
Timeframe: Blood samples collected over 36 hour period

Interventionng*h/mL (Mean)
Amlodipine Benazepril1645.73
Lotrel®1631.10

[back to top]

AUC0-t - Amlodipine

Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant) (NCT00835367)
Timeframe: Blood samples collected over 168 hour period

Interventionpg*h/mL (Mean)
Amlodipine Benazepril329314.07
Lotrel®322615.55

[back to top]

AUC0-t - Benazepril

Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant) (NCT00835367)
Timeframe: Blood samples collected over 36 hour period

Interventionng*h/mL (Mean)
Amlodipine Benazepril197.23
Lotrel®190.74

[back to top]

AUC0-t - Benazeprilat

AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant) (NCT00835367)
Timeframe: Blood samples collected over 36 hour period

Interventionng*h/mL (Mean)
Amlodipine Benazepril1611.85
Lotrel®1597.94

[back to top]

Endothelial Dysfunction

Post hyperemia increase in blood flow - fold increase from before and after occluding BP; values are mean of all participants in 6-36 months of study period. (NCT00907374)
Timeframe: 6 to 36 months

InterventionFold increase (Mean)
Low Dose Inhibition of RAS2.2
Agressive Inhibition of the RAS2.0

[back to top]

Estimated Glomerular Filtration Rate

This is an average for all participants during the 3-36 month study period (NCT00907374)
Timeframe: 3 to 36 months

Interventionml/min/1.73 meters squared (Mean)
Low Dose Inhibition of RAS108.7
Agressive Inhibition of the RAS100.5

[back to top]

Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio

Average of ratio for all participants during the 3-36 months of the study (NCT00907374)
Timeframe: 3 to 36 months

InterventionRatio (Mean)
Low Dose Inhibition of RAS256.1
Agressive Inhibition of the RAS376.2

[back to top]

Carotid Artery Intima Thickness

Thickness of intima of right carotid artery; average of all particpants from 6-36 months of study (NCT00907374)
Timeframe: 6 to 36 months

Interventionmm (Mean)
Low Dose Inhibition of RAS0.74
Agressive Inhibition of the RAS0.72

[back to top]

Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter

(NCT01234922)
Timeframe: 7 days post-baseline

InterventionPicogram/milliliter (Mean)
Arm I13.25
Arm II33.67
Arm III6.685
Arm IV5.045

[back to top]

Endothelial Function

Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use. (NCT01603940)
Timeframe: 12 weeks

Interventionpercentage of maximal vasodilation (Median)
Losartan9.4
Benazepril8.8

[back to top]

Vascular Stiffness

Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril). (NCT01603940)
Timeframe: 12 weeks.

Interventionm/s (Median)
Losartan8.5
Benazepril8.5

[back to top]

Diastolic Blood Pressure

Compare both group effects on diastolic blood pressure. (NCT01603940)
Timeframe: 12 weeks

InterventionmmHg (Median)
Losartan80
Benazepril82

[back to top]

Vascular Stiffness by Augmentation Index

Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups. (NCT01603940)
Timeframe: 12 weeks

Interventionpercentage of augmentation pressure (Median)
Losartan28
Benazepril35

[back to top]

Systolic Blood Pressure

Compare both groups effects on systolic blood pressure. (NCT01603940)
Timeframe: 12 weeks

InterventionmmHg (Median)
Losartan134
Benazepril139

[back to top]

Postoperative Hypotension

Any systolic blood pressure less than 90 mmHg (NCT01669434)
Timeframe: Arrival in PACU to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission15
ACEI Continuation31

[back to top]

Postoperative Hypertension

Any systolic blood pressure greater than 180 mmHg. (NCT01669434)
Timeframe: Arrival in PACU to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission33
ACEI Continuation17

[back to top]

Older Age Subgroup

Only patients above the age of 64 will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission48
ACEI Continuation49

[back to top]

Number of Participants With Interoperative Hypotension

Number of Participants with Interoperative Hypotension (systolic blood pressure under 80 mmHg) (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission76
ACEI Continuation95

[back to top]

Low Blood Pressure Subgroup

Only patients with systolic blood pressure less than 110 at preoperative evaluation will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg. (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission4
ACEI Continuation2

[back to top]

Acute Renal Failure

Creatinine increase of more than 0.3 mg/dl or more than 50% from preoperative level (NCT01669434)
Timeframe: Arrival in post-anesthesia care unit (PACU) to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission6
ACEI Continuation10

[back to top]